London, United Kingdom (PressExposure) July 27, 2011 -- GlobalData's analysis shows that the Staphylococcal infections therapeutics market grew at a compound annual growth rate (CAGR) of 13.4% from $1.6 billion in 2005 to reach $3.0 billion in 2010. The Staphylococcal infections therapeutics market is set to show moderate growth in the forecast period at a CAGR of 4.2%, from $3.0 billion in 2010 to $4.0 billion in 2017. The moderate growth in the market can be attributed to the increase in the number of immunocompromised patients, along with increased elderly patient population. The entry of new antibiotics with better safety and efficacy than the existing antibiotics to which the patients have developed resistance will also drive the market. The market is expected to witness a slight decline after 2015 due to the patent expiry of major antibiotics, such as Zyvox and Cubicin in late 2014 and mid 2016, respectively. The present marketed products for the treatment ofStaphylococcal infections have significant efficacy and safety standards. However, the segment of the Staphylococcal market comprising of prophylaxis of staphylococcal infections, yet remains an untapped area. Research and development is the key for pharmaceutical companies to bring a novel vaccine to the market to capitalize on this opportunity.
Global Data analysis expects torezolid and cefatroline to receive approval from the US Food and Drug
Administration (FDA) and European Medicines Agency (EMEA) in the near future. These drugs have higher efficacy and safety profiles for the treatment of Staphylococcal infections in comparison with the
currently available drugs in the market, making them promising future players in the Staphylococcal infections therapeutics market. Also, the significant morbidity, mortality and cost aligned with drug resistant Staphylococcal infections will allow the future players in the Staphylococcal infections therapeutics market to justify the relatively premium pricing of the antibiotics in the market.
The current Staphylococcal therapeutics market is strong due to the presence of four branded antibiotics: Zyvox (linezolid), Cubicin (daptomycin), Vibativ (telavancin) and Tygacil (tigecycline). Many generic antibiotics are also present in the Staphylococcal infections therapeutics market, such as Synercid (quinupristin, dalfopristin) and vancomycin. Teflaro, a fifth generation cephalosporin recently launched in the US market is expected to significantly increase the future competition. Pfizer, Theverence, Cubist and Forest pharmaceuticals are the leading players in the global Staphylococcal infections therapeutics market. Zyvox and Cubicin are the current market leaders in the staphylococcal infections therapeutics market and are expected to retain their position for the next three to four years.
For Sample Pages, please click or add the below link to your browser:
The Staphylococcal infections therapeutics pipeline consists of 61 products in different stages of clinical
development as of June, 2011. The Phase III stage of clinical development consists of eight molecules,
Phase II of 22 molecules and Phase I consists of 11 molecules. The molecules in the pipeline can be categorized on the basis of their mechanism of action as 28 first-in-class molecules, 17 me-too products,
one product extensions and two generic molecules.
GlobalData, the industry analysis specialist, has released its new report, "Staphylococcal Infections
Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source
of information and analysis on the global staphylococcal infections therapeutics market. The report
identifies the key trends shaping and driving the global staphylococcal infections therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global staphylococcal infections therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com/reportstore
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782